- Novel thrombin-based topical hemostat controls bleeding from vascular access sites
- Designed specifically for use around indwelling lines up to 12F
- Contains antimicrobial properties of silver chloride
MINNEAPOLIS, Jan. 21, 2014 (GLOBE NEWSWIRE) -- Vascular Solutions, Inc. (Nasdaq:VASC) today announced the U.S. market launch of ThrombiDisc topical hemostat, a thrombin-based pad used as an adjunct to manual compression to control surface bleeding from vascular access sites and percutaneous catheters or tubes.
The ThrombiDisc topical hemostat is a sterile pad 1" in diameter containing lyophilized bovine thrombin, a protein substance that gives the bandage its bleeding control properties, and silver chloride, which provides antimicrobial properties. A pre-formed slit and a 4mm diameter hole in the center of the pad allow easy placement of ThrombiDisc around indwelling lines up to 12 French in diameter.
"Effective control of bleeding around indwelling vascular access devices such as central venous catheters and peripherally-inserted central catheters is a clinical imperative that ThrombiDisc was designed specifically to meet," said Howard Root, Chief Executive Officer of Vascular Solutions. "ThrombiDisc builds on Vascular Solutions' long experience in the use of lyophilized bovine thrombin as a topical hemostat in a variety of clinical settings. While other pads placed around indwelling lines merely absorb blood, ThrombiDisc addresses the bleeding problem with an active ingredient. In vitro testing has demonstrated ThrombiDisc's ability to create a much quicker clot compared to the two most popular alternatives."
ThrombiDisc also contains the antimicrobial ingredient silver chloride. In the presence of fluids, such as blood and wound fluids, ionic silver is released from the silver chloride to prevent microorganisms commonly encountered in the clinical setting from colonizing on the pad. Ionic silver, an atom of silver that is missing one electron, provides its antimicrobial property by altering protein structures and preventing bacterial cells from carrying out normal functions.
About ThrombiDisc Topical Hemostat
ThrombiDisc topical hemostat consists of a lyophilized pad containing bovine thrombin, silver chloride, sodium carboxymethylcellulose, and calcium chloride in a nonwoven gauze. The 1" sterile disc is placed directly over the source of the bleeding as an adjunct to manual compression. The pre-formed slit and 4mm diameter hole in the ThrombiDisc allow for placement around indwelling lines up to 12F. In vitro testing demonstrated that representative samples of ThrombiDisc killed at least 99.99% of seven common microbes known to cause catheter-related bloodstream infections (CRBSIs) after 24 hours of contact. The antimicrobial properties of ThrombiDisc have not been clinically tested, and the in vitro test results have not been determined to correlate with a reduction in infections. Indications: ThrombiDisc hemostatic bandage is applied topically as an adjunct to manual compression and is indicated for the control of surface bleeding from vascular access sites and percutaneous catheters or tubes. ThrombiDisc contains silver chloride to prevent microorganisms commonly encountered in the clinical setting from colonizing on the pad. Contraindications: ThrombiDisc is contraindicated in persons with known sensitivity to bovine-derived materials.
About Vascular Solutions
Vascular Solutions, Inc. is an innovative medical device company that focuses on developing unique clinical solutions for coronary and peripheral vascular procedures. The company's product line consists of more than 75 products in three categories: catheter products, hemostat products and vein products. Vascular Solutions delivers its products to interventional cardiologists, interventional radiologists, electrophysiologists, and vein specialists through its direct U.S. sales force and international independent distributor network.
The information in this press release contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements. Important factors that may cause such differences include those discussed in our Annual Report on Form 10-K for the year ended December 31, 2012 and other recent filings with the Securities and Exchange Commission. The risks and uncertainties include, without limitation, risks associated with the need for adoption of our new products, lack of sustained profitability, exposure to intellectual property claims, significant variability in quarterly results, exposure to possible product liability claims, the development of new products by others, doing business in international markets, the availability of third party reimbursement, and actions by the FDA.
For further information, connect to www.vasc.com.